Eupraxia Pharmaceuticals, Inc. (EPRX)
7.50
+0.05
(+0.67%)
USD |
NASDAQ |
Sep 03, 16:00
7.50
0.00 (0.00%)
After-Hours: 20:00
Eupraxia Pharmaceuticals Enterprise Value : 383.88M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 383.88M |
| September 01, 2026 | 311.21M |
| August 31, 2026 | 319.07M |
| August 28, 2026 | 333.14M |
| August 27, 2026 | 377.99M |
| August 26, 2026 | 382.58M |
| August 25, 2026 | 381.92M |
| August 24, 2026 | 372.75M |
| August 21, 2026 | 336.74M |
| August 20, 2026 | 338.71M |
| August 19, 2026 | 355.08M |
| August 18, 2026 | 344.60M |
| August 17, 2026 | 342.64M |
| August 14, 2026 | 336.09M |
| August 13, 2026 | 332.82M |
| August 12, 2026 | 320.38M |
| August 11, 2026 | 334.78M |
| August 10, 2026 | 332.16M |
| August 07, 2026 | 339.36M |
| August 06, 2026 | 332.16M |
| August 05, 2026 | 320.38M |
| August 04, 2026 | 322.99M |
| August 03, 2026 | 322.34M |
| July 31, 2026 | 315.14M |
| July 30, 2026 | 324.96M |
| Date | Value |
|---|---|
| July 29, 2026 | 286.98M |
| July 28, 2026 | 295.49M |
| July 27, 2026 | 300.08M |
| July 24, 2026 | 276.51M |
| July 23, 2026 | 308.59M |
| July 22, 2026 | 316.45M |
| July 21, 2026 | 313.83M |
| July 20, 2026 | 304.66M |
| July 17, 2026 | 327.58M |
| July 16, 2026 | 299.42M |
| July 15, 2026 | 322.99M |
| July 14, 2026 | 311.21M |
| July 13, 2026 | 317.10M |
| July 10, 2026 | 333.47M |
| July 09, 2026 | 348.53M |
| July 08, 2026 | 349.18M |
| July 07, 2026 | 331.51M |
| July 06, 2026 | 322.99M |
| July 02, 2026 | 334.12M |
| July 01, 2026 | 335.43M |
| June 30, 2026 | 328.89M |
| June 29, 2026 | 298.59M |
| June 26, 2026 | 299.21M |
| June 25, 2026 | 287.46M |
| June 24, 2026 | 277.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 43.93M |
| ProMIS Neurosciences, Inc. | 71.86M |
| Arrowhead Pharmaceuticals, Inc. | 11.82B |
| Oncolytics Biotech, Inc. | 106.01M |
| Sangamo Therapeutics, Inc. | 62.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.49M |
| Total Expenses (Quarterly) | 14.49M |
| EPS Diluted (Quarterly) | -0.2278 |
| Earnings Yield | -13.13% |
| Normalized Earnings Yield | -13.13 |